Ovarian cancer is the fifth leading cause of cancer death in women and often presents late due to vague symptoms. It originates in the ovaries and frequently spreads to the peritoneum before diagnosis.
Olaparib is a PARP inhibitor that exploits DNA repair defects in BRCA-mutated tumors, used to treat ovarian and breast cancers.
Niraparib is a PARP inhibitor that exploits DNA repair defects in BRCA-mutated tumors, used to treat ovarian and breast cancers.
Rucaparib is a PARP inhibitor that exploits DNA repair defects in BRCA-mutated tumors, used to treat ovarian and breast cancers.
Describe your symptoms and get a structured AI clinical assessment — possible causes, urgency level, and recommended next steps.
Start Free AI Analysis →Content on this page is informed by evidence-based clinical sources including: